Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...

Royal Bank of Canada reissued their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They ...

Citigroup has shown significant progress in ... Exiting the expense-intensive phase of its operational restructuring, Citi looks set to drive meaningful revenue growth on improved competitive ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) had its price target lowered by equities researchers at Needham & Company LLC from $38.00 to $10.00 in a report released on Monday,Benzinga reports.

The former Florida Coastal School of Law building got the top score in the first phase of Citizens Property Insurance's ...

Slate Asset Management has acquired 2283 Third Ave., an 18-unit rental in East Harlem, from Rockfeld Group for $28.3M, ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

The market is paying particularly close attention to Q4 earnings, given the S&P 500’s lofty valuation. Potential tariffs and ...

CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...